Imaging Esophageal Cancer with Fluorescent Antibodies
Part of Cancer, Digestive system clinical trials.
This trial tests whether special fluorescent dyes attached to immune drugs can help doctors see esophageal cancer more clearly during an endoscopy. It may help guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have locally advanced esophageal cancer (cT1b-4a N0-3 M0).
- You are scheduled for chemotherapy before surgery or definitive chemoradiation.
- You are 18 years or older.
- You are able to give written informed consent.
- No active autoimmune disease requiring treatment.
- Not pregnant or breastfeeding (a pregnancy test will be done if needed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether detailed scans taken before treatment can predict how well chemo and immunotherapy will work for advanced esophageal cancer. The goal is to improve treatment planning and potentially reduce side effects by personalizing care.
This trial uses advanced imaging tests (spectral CT, multimodal MRI, and FAPI PET-CT) before surgery to find if esophageal cancer has spread to lymph nodes. The goal is to improve how doctors predict and diagnose lymph node metastasis using these scans, along with pathology and AI analysis.
This trial uses CT and MRI scans before and after chemotherapy or radiation to see how well the treatment worked in esophageal cancer. The goal is to match scan results with what doctors find after surgery.
This trial compares two treatment sequences for people with locally advanced esophageal cancer that cannot be removed with surgery. One group gets immunotherapy first, then chemoradiation; the other gets chemoradiation first, then immunotherapy. The goal is to find which order works better.
This Phase 2 study uses special drug dyes (bevacizumab and cetuximab, each tagged for imaging) during an esophagus scope to help doctors find very early abnormal cells, like low- or high-grade pre-cancer and superficial cancer. If you qualify, the goal is earlier detection and better targeting during diagnosis and treatment.
This study tests a special dye attached to durvalumab (a cancer drug) to see if it can light up tumors in the lungs during a bronchoscopy. It will help doctors see if the drug reaches the cancer cells and may guide future treatments.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.